Galectin Therapeutics to Hold Conference Call to Provide Update Following Company’s Annual Meeting of Shareholders

  Galectin Therapeutics to Hold Conference Call to Provide Update Following
  Company’s Annual Meeting of Shareholders

Business Wire

NEWTON, Mass. -- May 22, 2012

Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 10:00 A.M.
Eastern Time on Thursday, May 24, 2012, to provide an update following the
Company’s Annual Meeting of Shareholders. Additionally, Peter Traber, MD,
President, CEO and CMO of Galectin Therapeutics, will update the investment
community on the Company’s pipeline of galectin inhibitor compounds in liver
fibrosis and cancer.

The conference call and presentation will be webcast live over the internet
and can be accessed by logging on to the Galectin Therapeutics website at The call can also be accessed by dialing (866)
804-6929 (within the United States) or (857) 350-1675 (outside the United
States). The passcode for participants is 46228838. Please log in
approximately 10 minutes before the event to ensure a timely connection.

A replay of the call will be available after the live call concludes through
June 7, 2012. To access the replay, dial (888) 286-8010 (within the United
States) or (617) 801-6888 (outside the United States). The passcode is
58856118. The webcast will also be archived on the Company's website.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for fibrotic liver disease and cancer based on
the Company's unique understanding of galectin proteins, key mediators of
biologic function. We are leveraging extensive scientific and development
expertise as well as established relationships with external sources to
achieve cost effective and efficient development. We are pursuing a clear
development pathway to clinical enhancement and commercialization for our lead
compounds in liver fibrosis and cancer. Additional information is available at

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as “may,” “estimate,”
“could,” “expect” and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.


Galectin Therapeutics Inc.
Maureen Foley, 617-559-0033
Chief Operating Officer
Press spacebar to pause and continue. Press esc to stop.